Business
Aptorum Group Appoints Dr. Herman Weiss as CEO of microbiome-based platform Claves Life Sciences and Dr. Robbie Majzner as scientific advisor to SACT-1 drug for Neuroblastoma and others
NEW YORK & LONDON--(BUSINESS WIRE)-- Regulatory News: Aptorum Group Limited (NASDAQ: APM, Euronext Paris: APM), a biopharmaceutical company focused on the
About this update from Aptorum Group Limited
[{"type":"text","content":"\n \n\n NEW YORK & LONDON--(BUSINESS WIRE)--\nRegulatory News:\n\n\nAptorum Group Limited (NASDAQ: APM, Euronext Paris: APM), a biopharmaceutical company focused on the development of novel therapeutics to address certain global unmet medical needs, today announced two appointments to its team.\n\n\nAppointment of Dr. Herman Weiss MD as CEO and Executive Director of Claves Life Sciences\n\n\nDr. Herman Weiss, M.D., has been appointed as the Chief Executive Officer and Executive Director of Claves Life Sciences Limited (“Claves”) and also senior medical advisor of Aptorum Group Limited (“Aptorum Group” or “Company”). Claves is one of Aptorum Group’s wholly-owned subsidiaries and is focused on microbiome-based approach to metabolic diseases. Going forward, Dr. Weiss will be leading the development of Claves’ business and drive Claves’ exciting microbiome-based research platform for treatments of metabolic diseases, and potentially other indications, to targeted clinical stages. Claves is a microbiome-based platform utilizing proprietary macromolecule-based technology to target major systemic metabolic diseases including microbiome modulator CLS-1 for treatment of obesity. Through Claves, the Company is also developing microbiome modulators CLS-2 and CLS-3, which target other metabolic diseases.\n\n\nAppointment of Dr. Robbie Majzner as scientific advisor of Aptorum Group\n\n\nDr. Robbie Majzner has been appointed as a scientific advisor of Aptorum Group Limited. In particular, Dr. Majzner will provide scientific advice and support for certain targeted clinical development aspects of Aptorum Group’s repurposed drug candidate SACT-1 for the treatment of neuroblastoma, a rare type of solid tumor cancer that develops predominantly in infants and young children, as well as other potential cancer indications.\n\n\n“We are delighted that Dr. Weiss and Dr. Majzner are joining the Aptorum Group family. as the Chief Executive Officer of Claves, Dr. Weiss, who served at Juniper Pharmaceuticals Inc., which was previously listed on Nasdaq and was subsequently acquired in 2018 by Catalent Inc (NYSE: CTLT), brings with him significant clinical development experience which will be critical in driving R&D of Claves’ microbiome-based drug candidates to the next targeted development milestones. We are also delighted to have Dr. Majzner, a world-clas...